Sonire Therapeutics awarded $13m from Japanese government-backed innovation agency

NEDO’s grant and expertise will support Sonire right through to the market adoption stage of its pancreatic cancer treatment. NEDO’s grant and expertise will support Sonire right through to the market adoption stage of its pancreatic cancer treatment. High-intensity focused ultrasound (HIFU) is one of the emerging non-invasive modalities for the treatment of pancreatic cancer. Credit: mi_viri / Shutterstock.com The government of Japan has inducted Sonire Therapeutics’ Japan-based group into an innovation programme, along with equipping the company with a $13m grant to support the development of Suizenji, an ultrasound-based system for pancreatic cancer treatment. The funds for Sonire Therapeutics…

Source: Medical Device Network